4baseCare

4baseCare is a precision oncology company that harnesses genomic diversity, real-world data, and artificial intelligence to personalize cancer care for patients across the globe. Founded on the principle that cancer behaves differently across populations — and that most global treatment data fails to represent the full diversity of those populations — 4baseCare combines advanced genomics, deep clinico-genomic datasets, and AI-powered analytics to deliver actionable, personalized insights to clinicians, hospitals, pharmaceutical companies, and researchers.

Headquartered with a multi-country laboratory network, 4baseCare serves oncologists, hospitals, pharma trial teams, and pharma research organizations. The company has been recognized at the MSK Innovation Hub Challenge 2025 at Memorial Sloan Kettering Cancer Center, has partnered with Owkin to advance inclusive AI-driven cancer research, and has signed an MoU with Bio Valley Incubation Council and Define Bio to build India's next-generation genomics ecosystem at AMTZ. Its leadership has been honored with the Entrepreneur of the Year award at the BioSpectrum India Excellence Awards 2025.

Global Cancer Diversity Atlas (GCDA)

• The world's first atlas capturing cancer's genomic diversity across underrepresented populations worldwide.
• Over 23,000 genomic profiles mapped from unique, underrepresented cancer populations.
• Covers 12 or more rare and under-studied cancers, including thyroid, gall bladder, sarcomas, and others largely absent from global datasets.
• Represents data from 8 or more countries, expanding precision oncology insights across regions.
• Encompasses 70 or more cancer types with multidimensional data, integrating tumor, germline, liquid biopsy, clinical, and outcomes datasets.
• Designed to reshape precision oncology by ensuring global cancer knowledge networks are truly inclusive.

OncoTwin — AI-Powered Intelligence Platform

• A unified platform combining clinico-genomic data, real-world evidence, and AI to advance treatment decisions, biomarker discovery, trial design, and molecular tumor board (MTB) collaboration.
• Clinical Decision Support with Patient Twin Matching: Identifies clinically similar patients across tumor type, stage, biomarkers, treatments, and outcomes to deliver precise, evidence-backed treatment recommendations for oncologists.
• AI-Enhanced Intelligence for Molecular Tumor Boards: Integrates genomic data, clinical history, treatment insights, and real-world evidence into one unified workspace, enabling faster, sharper, and consensus-driven MTB decision-making for hospitals.
• AI-Powered Clinical Trial Optimization: Enhances trial feasibility, patient stratification, and site selection using real-world cohorts and AI-driven digital twin modeling to improve recruitment and trial outcomes for pharma trial teams.
• Real-World Evidence-Based Biomarker and Drug Discovery: Utilizes diverse, multi-modal real-world datasets to accelerate biomarker discovery, validate therapeutic hypotheses, and generate evidence supporting regulatory and scientific advancement for pharma research.

Genomic Testing Portfolio

• Tissue Profiling (Solid Tumor Genomics): Comprehensive tumor DNA and RNA profiling from FFPE blocks that identifies actionable mutations, fusions, signatures, and resistance mechanisms to guide targeted therapy, immunotherapy, and precision treatment decisions.
• Liquid Profiling (ctDNA Analysis): High-sensitivity circulating tumor DNA testing that detects actionable mutations, tracks treatment response, and overcomes tissue limitations through real-time, non-invasive genomic assessment.
• SoLiQ Dual-Source Genomics: A combined tissue–liquid–germline approach that overcomes tumor heterogeneity, confirms true somatic variants, and delivers the most complete and clinically confident genomic picture for each patient.
• HRD Testing (PARPredict): A scar-based HRD assay that measures genomic instability to identify HRD-positive tumors more accurately than BRCA-only testing, enabling confident PARP inhibitor therapy selection.
• Germline Cancer Risk and Treatment Insights: Hereditary cancer testing that identifies inherited risk variants, informs treatment sensitivity including PARP inhibitor eligibility, and supports family counseling and preventive care.

Patient Initiatives

• LuNGS Alliance (CRSF & 4baseCare): Provides free NGS biomarker testing for eligible lung cancer patients across India.
• Hope Initiative (AIIMS Jammu & 4baseCare): A joint effort to make advanced genomic testing affordable and accessible for every cancer patient in India.
• OncoBuddy: A no-cost platform enabling cancer survivors and caregivers to share their journeys and build community support.

Leadership and Advisory Board

• CEO and Co-Founder Hitesh Goswami brings over 20 years of experience in pharma drug discovery, genomics, and precision medicine, with prior roles at Piramal Life Sciences and as co-founder of Bionivid Technology.
• COO and Co-Founder Kshitij Rishi, an XLRI alumnus with leadership experience at Deloitte and GE, oversees strategic partnerships, real-world evidence initiatives, and patient engagement programs.
• Chief Scientific Officer Dr. Giridharan Periyasamy has over 22 years of experience in cancer biology, drug discovery, and translational genomics, with roles at Piramal Life Sciences, CCAMP–NCBS Bangalore, and A*STAR Singapore.
• Chief Digital Officer Puneet Vijay Pantane brings nearly 25 years of experience in digital healthcare transformation, with expertise spanning AI, ML, NLP, radiology, pathology, cardiology, and critical care.
• Additional senior leaders include VP Commercial Operations Praveen Jha, VP RWE Strategy & Analytics Dr. Anjali Kulkarni, VP Clinical Operations Dr. Vidya Harini Veldore (IISc alumna), VP Global Operations & Regulations Dr. Sudharshan Elangovan, Head of Patient Care & Engagement Dr. Rahul Kumar, and Finance Controller Rahul Jha.
• The advisory board includes Mr. Lip Bu Tan (CEO, Intel), Mr. Francis de Souza (COO, Google Cloud; former CEO, Illumina), and Prof. George Church (Professor at Harvard and MIT).

4baseCare is building a new standard of cancer care that is inclusive, data-driven, and powered by the genomic diversity of the world's populations — working to ensure that every patient, everywhere, has access to personalized, evidence-backed oncology decisions.